Survival and Proliferation Factors of Normal and Malignant Plasma Cells (original) (raw)

• Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.Blood. 1999;94:701–712.
  PubMed CAS Google Scholar
• Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.Blood. 2002;100:1113–1122.
  PubMed CAS Google Scholar
• Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells.Annu Rev Immunol. 2003;21:205–230.
  Article PubMed CAS Google Scholar
• Jung J, Choe J, Li L, Choi YS. Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10.Eur J Immunol. 2000;30:2437–2443.
  Article PubMed CAS Google Scholar
• Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction.Blood. 1998;91:173–180.
  PubMed CAS Google Scholar
• Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.Science. 1988;241:825–828.
  Article PubMed CAS Google Scholar
• Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice.Proc Natl Acad Sci U S A. 1989;86:7547–7551.
  Article PubMed PubMed Central CAS Google Scholar
• Kopf M, Baumann H, Freer G, et al. Impaired immune and acutephase responses in interleukin-6-deficient mice.Nature. 1994;368:339–342.
  Article PubMed CAS Google Scholar
• Wen XY, Stewart AK, Sooknanan RR, et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.Int J Oncol. 1999;15:173–178.
  PubMed CAS Google Scholar
• Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1.Nature. 2001;412:300–307.
  Article PubMed CAS Google Scholar
• Hirano T. Interleukin 6 and its receptor: ten years later.Int Rev Immunol. 1998;16:249–284.
  Article PubMed CAS Google Scholar
• Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma.Nature. 1988;332:83–85.
  Article PubMed CAS Google Scholar
• Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood. 1989;73:517–526.
  PubMed CAS Google Scholar
• Zhang XG, Bataille R, Widjenes J, Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.Cancer. 1992;69:1373–1376.
  Article PubMed CAS Google Scholar
• Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.Blood. 1991;78:1198–1204.
  PubMed CAS Google Scholar
• Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of antiinterleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma.Blood. 1995;86:685–691.
  PubMed CAS Google Scholar
• Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.Blood. 1995;86:3123–3131.
  PubMed CAS Google Scholar
• Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias.J Clin Invest. 1989;84:2008–2011.
  Article PubMed PubMed Central CAS Google Scholar
• Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.Eur J Immunol. 1993;23:820–824.
  Article PubMed CAS Google Scholar
• Portier M, Rajzbaum G, Zhang XG, et al. In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma.Eur J Immunol. 1991;21:1759–1762.
  Article PubMed CAS Google Scholar
• Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production.Br J Haematol. 1998;103:1152–1160.
  Article PubMed CAS Google Scholar
• Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.Proc Natl Acad Sci U S A. 1996;93:4885–4890.
  Article PubMed PubMed Central CAS Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.Blood. 1993;82:3712–3720.
  PubMed CAS Google Scholar
• Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.Blood. 1994;84:2269–2277.
  PubMed CAS Google Scholar
• Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.Blood. 1994;83:3654–3663.
  PubMed CAS Google Scholar
• Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin-6 transgenic mice.Proc Natl Acad Sci U S A. 1989;86:7547–7551.
  Article PubMed PubMed Central CAS Google Scholar
• Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.Proc Natl Acad Sci U S A. 1992;89:232–235.
  Article PubMed PubMed Central CAS Google Scholar
• Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.Am J Pathol. 1997;151:689–696.
  PubMed PubMed Central CAS Google Scholar
• Zhang XG, Gu ZJ, Lu ZY, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.J Exp Med. 1994;179:1337–1342.
  Article PubMed CAS Google Scholar
• Klein B. Growth factors in the pathogenesis of multiple myeloma. In: Garthon L, Durie BGM, eds.Multiple Myeloma. London: Edward Arnold Publishers; 1996:73–82.
  Google Scholar
• Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induced autocrine production of IL-6 in myeloma cell lines.J Immunol. 1991;147:4402–4407.
  PubMed CAS Google Scholar
• Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.J Immunol. 1998;161:2692–2699.
  PubMed CAS Google Scholar
• Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.J Biol Chem. 1998;273:11799–11805.
  Article PubMed CAS Google Scholar
• Lu ZY, Zhang XG, Wijdenes J, et al. Interleukin-10 is a growth factor for human myeloma cells.Blood. 1995;85:2521–2527.
  PubMed CAS Google Scholar
• Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.Blood. 1996;88:3972–3986.
  PubMed CAS Google Scholar
• De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogenactivated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.Br J Haematol. 2000;109:823–828.
  Article PubMed Google Scholar
• Jourdan M,Vos JD, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.Cell Death Differ. 2000;7:1244–1252.
  Article PubMed CAS Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.Immunity. 1999;10:105–115.
  Article PubMed CAS Google Scholar
• Puthier D, Derenne S, Barille S, et al. Mcl-1 and bcl-xL are co-regulated by IL-6 in human myeloma cells.Br J Haematol. 1999;107:392–395.
  Article PubMed CAS Google Scholar
• Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.Blood. 2002;100:194–199.
  Article PubMed CAS Google Scholar
• Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.Oncogene. 2003;22:2950–2959.
  Article PubMed PubMed Central CAS Google Scholar
• Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/ AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.Cancer Res. 2000;60:6763–6770.
  PubMed CAS Google Scholar
• Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor.Science. 1997;276:1418–1420.
  Article PubMed CAS Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene. 2002;21:5673–5683.
  Article PubMed CAS Google Scholar
• Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.Blood. 2002;99:4138–4146.
  Article PubMed CAS Google Scholar
• Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.Oncogene. 2002;21:6587–6597.
  Article PubMed CAS Google Scholar
• Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulinlike growth factor I is a growth and survival factor in human multiple myeloma cell lines.Blood. 1996;88:2250–2258.
  PubMed CAS Google Scholar
• Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth.J Immunol. 1997;159:487–496.
  PubMed CAS Google Scholar
• Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.Br J Haematol. 2000;111:626–634.
  Article PubMed CAS Google Scholar
• Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.Blood. 2000;96:2856–2861.
  PubMed CAS Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene. 2001;20:5991–6000.
  Article PubMed CAS Google Scholar
• Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.Oncogene. 2002;21:1391–1400.
  Article PubMed CAS Google Scholar
• Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.Oncogene. 2000;19:4091–4095.
  Article PubMed CAS Google Scholar
• Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.Blood. 2002;100:3925–3929.
  Article PubMed CAS Google Scholar
• Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins.J Endocrinol. 2002;175:41–54.
  Article PubMed CAS Google Scholar
• De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.Blood. 2001;98:771–780.
  Article PubMed Google Scholar
• Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.Br J Haematol. 1996;94:318–323.
  Article PubMed CAS Google Scholar
• Costes V, Magen V, Legouffe E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.Hum Pathol. 1999;30:1405–1411.
  Article PubMed CAS Google Scholar
• Zimmermann P, David G. The syndecans, tuners of transmembrane signaling.Faseb J. 1999;13:S91-S100.
  Article PubMed CAS Google Scholar
• Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.Oncogene. 2002;21:2584–2592.
  Article PubMed CAS Google Scholar
• Davis-Fleischer KM, Besner GE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF).Front Biosci. 1998;3:d288–299.
  Article PubMed CAS Google Scholar
• Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGFrelated peptides in tumor growth.Front Biosci. 2001;6:D685–707.
  Article PubMed CAS Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy.Oncogene. 2000;19:6550–6565.
  Article PubMed CAS Google Scholar
• Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.Blood. 2002;99:1405–1410.
  Article PubMed CAS Google Scholar
• Seidel C, Borset M,Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.Blood. 1998;91:806–812.
  PubMed CAS Google Scholar
• Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.Blood. 1999;94:3883–3888.
  PubMed CAS Google Scholar
• Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.Cancer Res. 1998;58:5640–5645.
  PubMed CAS Google Scholar
• Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.Br J Haematol. 2002;117:626–628.
  Article PubMed CAS Google Scholar
• Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.Nat Genet. 1997;16:260–264
  Article PubMed PubMed Central CAS Google Scholar
• Sato N, Hattori Y, Wenlin D, et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.Jpn J Cancer Res. 2002;93:459–466.
  Article PubMed PubMed Central CAS Google Scholar
• Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.Mol Biol Cell. 2001;12:931–942.
  Article PubMed PubMed Central CAS Google Scholar
• Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.Blood. 2001;97:729–736.
  Article PubMed CAS Google Scholar
• Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.Blood. 2002;100:3819–3821.
  Article PubMed CAS Google Scholar
• Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update.Curr Opin Immunol. 2002;14:783–790.
  Article PubMed CAS Google Scholar
• Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells.Nat Rev Immunol. 2002;2:465–475.
  Article PubMed CAS Google Scholar
• Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma.Blood. 2002;100:2175–2186.
  Article PubMed CAS Google Scholar
• Tarte K, Moreaux J, Legouffe E, Rossi JF, Klein B. BAFF is a survival factor for multiple myeloma cells.Blood. 2002
• French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells.J Immunol. 2003;170:3717–3723.
  Article PubMed CAS Google Scholar
• Walters DK, French JD, Arendt BK, Jelinek DF. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex.Oncogene. 2003;22:3598–3607.
  Article PubMed CAS Google Scholar
• Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.J Biol Chem. 2003;278:5794–5801.
  Article PubMed CAS Google Scholar
• Charrin S, Le Naour F, Oualid M, et al. The major CD9 and CD81 molecular partner. Identification and characterization of the complexes.J Biol Chem. 2001;276:14329–14337.
  Article PubMed CAS Google Scholar